AnaptysBio Inc.
| NASDAQ: ANAB | Healthcare / Biotechnology / USA |
| 18.39 | -0.0400 | -0.22% | Vol 86.99K | 1Y Perf -31.66% |
| Oct 4th, 2023 15:34 DELAYED |
| BID | 18.37 | ASK | 18.41 | ||
| Open | 18.37 | Previous Close | 18.43 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 33.14 | Analyst Rating | Moderate Buy 2.20 | |
| Potential % | 80.21 | Finscreener Ranking | ★★★+ 51.32 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 50.95 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★+ 54.89 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 11.81 | Earnings Rating | Sell | |
| Market Cap | 488.17M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.20 | |
| Beta | -0.12 |
Today's Price Range 17.8618.41 | 52W Range 16.5132.44 | 5 Year PE Ratio Range -41.70-8.70 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.22% | ||
| 1 Month | -6.45% | ||
| 3 Months | -6.07% | ||
| 6 Months | -15.07% | ||
| 1 Year | -31.66% | ||
| 3 Years | 18.07% | ||
| 5 Years | -80.46% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -10.23 | |||
ROE last 12 Months | -40.79 | |||
ROA (5Y Avg) | -6.82 | |||
ROA last 12 Months | -25.86 | |||
ROC (5Y Avg) | -14.90 | |||
ROC last 12 Months | -34.28 | |||
Return on invested Capital Q | -9.53 | |||
Return on invested Capital Y | -8.34 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.80 | ||||
| 2.38 | ||||
| 179.87 | ||||
| 48.40 | ||||
| -10.50 | ||||
| 0.62 | ||||
| 2.38 | ||||
| 13.95 | ||||
| 237.34M | ||||
| Forward PE | -2.56 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 21.10 | ||||
| 21.40 | ||||
| 0.06 | ||||
| 0.07 | ||||
| -6.40 | ||||
| Leverage Ratio | 2.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 595.60 | ||||
| -2 548.50 | ||||
| -1 200.20 | ||||
| -76.88 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.48M | ||||
| 0.12 | ||||
| 131.31 | ||||
| 54.81 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -1.65 | -1.50 | 9.09 |
| Q01 2023 | -1.04 | -1.58 | -51.92 |
| Q04 2022 | -0.92 | -0.93 | -1.09 |
| Q03 2022 | -0.47 | -1.18 | -151.06 |
| Q02 2022 | -0.95 | -1.15 | -21.05 |
| Q01 2022 | -0.87 | -1.31 | -50.57 |
| Q04 2021 | 2.28 | -1.13 | -149.56 |
| Q03 2021 | -0.74 | -0.24 | 67.57 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -1.72 | -3.61 | Negative |
| 12/2023 QR | -1.79 | -9.82 | Negative |
| 12/2023 FY | -6.61 | 0.45 | Positive |
| 12/2024 FY | -6.99 | -9.73 | Negative |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -1.72 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 86.99K |
| Shares Outstanding | 26.55K |
| Shares Float | 14.55M |
| Trades Count | 2.33K |
| Dollar Volume | 1.58M |
| Avg. Volume | 251.02K |
| Avg. Weekly Volume | 198.90K |
| Avg. Monthly Volume | 294.68K |
| Avg. Quarterly Volume | 259.49K |
AnaptysBio Inc. (NASDAQ: ANAB) stock closed at 18.43 per share at the end of the most recent trading day (a 4.54% change compared to the prior day closing price) with a volume of 183.13K shares and market capitalization of 488.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 89 people. AnaptysBio Inc. CEO is Hamza Suria.
The one-year performance of AnaptysBio Inc. stock is -31.66%, while year-to-date (YTD) performance is -40.53%. ANAB stock has a five-year performance of -80.46%. Its 52-week range is between 16.51 and 32.435, which gives ANAB stock a 52-week price range ratio of 11.81%
AnaptysBio Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 2.38, a price-to-sale (PS) ratio of 179.87, a price to cashflow ratio of 48.40, a PEG ratio of -, a ROA of -25.86%, a ROC of -34.28% and a ROE of -40.79%. The company’s profit margin is -76.88%, its EBITDA margin is -2 548.50%, and its revenue ttm is $3.48 Million , which makes it $0.12 revenue per share.
Of the last four earnings reports from AnaptysBio Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.72 for the next earnings report. AnaptysBio Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for AnaptysBio Inc. is Moderate Buy (2.2), with a target price of $33.14, which is +80.21% compared to the current price. The earnings rating for AnaptysBio Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AnaptysBio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AnaptysBio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.22, ATR14 : 0.78, CCI20 : -40.76, Chaikin Money Flow : 0.02, MACD : -0.41, Money Flow Index : 21.66, ROC : -5.49, RSI : 47.89, STOCH (14,3) : 56.97, STOCH RSI : 1.00, UO : 60.85, Williams %R : -43.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AnaptysBio Inc. in the last 12-months were:
AnaptysBio Inc.
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.
CEO: Hamza Suria
Telephone: +1 858 362-6295
Address: 10421 Pacific Center Court, San Diego 92121, CA, US
Number of employees: 89
